A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)

Sponsor
Bing Han
Study ID
NCT06847607
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • AIHA - Cold Autoimmune Hemolytic Anemia
  • AIHA - Warm Autoimmune Hemolytic Anemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the efficacy and safety of ipecopam in the treatment of refractory/relapsed AIHA.

Key Dates

Start date
Mar 1, 2025
Status verified
Feb 2025
Primary completion
Oct 30, 2025
Completion
Jun 30, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Iptacopan-AIHA
    Iptacopan-AIHA

Primary Outcome Measure

OR [ Time Frame: 3 months ]

Central Contacts